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Epigenetic processes play a key role in the central nervous system and altered levels of 5-methylcytosine
have been associated with a number of neurologic phenotypes, including Alzheimer’s disease (AD).
Recently, 3 additional cytosine modiﬁcations have been identiﬁed (5-hydroxymethylcytosine,
5-formylcytosine, and 5-carboxylcytosine), which are thought to be intermediate steps in the deme-
thylation of 5-methylcytosine to unmodiﬁed cytosine. Little is known about the frequency of these
modiﬁcations in the human brain during health or disease. In this study, we used immunoﬂuorescence to
conﬁrm the presence of each modiﬁcation in human brain and investigate their cross-tissue abundance
in AD patients and elderly control samples. We identify a signiﬁcant AD-associated decrease in global 5-
hydroxymethylcytosine in entorhinal cortex and cerebellum, and differences in 5-formylcytosine levels
between brain regions. Our study further implicates a role for epigenetic alterations in AD.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is a chronic neurodegenerative disease
affecting >5.4 million adults in the US and contributing signiﬁ-
cantly to the global burden of disease (Thies and Bleiler, 2011).
Given the high heritability estimates for AD (Gatz et al., 2006),
considerable effort has focused on understanding the role of genetic
variation in disease etiology, although it has been recently specu-
lated that epigenetic dysfunction is also likely to be important
(Lunnon and Mill, 2013).ical School, St Luke’s Campus,
5 65; fax: þ44 1392 722 626.
).
l Sciences, Queen Mary Uni-
ll rights reserved.Epigenetics refers to the reversible regulation of various
genomic functions occurring independently of DNA sequence,
with cytosine methylation being the best-understood and most
stable epigenetic modiﬁcation modulating the transcription of
mammalian genomes. Recent studies have identiﬁed global- and
site-speciﬁc alterations in 5-methylcytosine (5-mC) levels in AD
brain (Bakulski et al., 2012; Mastroeni et al., 2009, 2010; Rao et al.,
2012).
A number of additional cytosine modiﬁcations have recently
been described. 5-hydroxymethylcytosine (5-hmC) has been
shown to be enriched in brain (Khare et al., 2012), suggesting it
may play an important role in neurobiological phenotypes and
disease. Importantly, current approaches based on sodium
bisulﬁte converted DNA are unable to distinguish between 5-mC
and 5-hmC (Nestor et al., 2010). 5-hmC is believed to be an in-
termediate step in the demethylation of 5-mC to unmodiﬁed
cytosine by the oxidation of 5-mC by ten eleven translocation
Fig. 1. Immunoﬂuorescence demonstrating the speciﬁcity of the antibodies used in this study. At the concentrations used no staining was observed in either the no primary
antibody control, or the nucleoside control. Staining of tissue (in absence of controls) was co-localized with 40 ,6-diamidino-2-phenylindole (DAPI) demonstrating nuclear staining.
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ciﬁc role in transcriptional regulation as it is recognized by key
proteins that do not recognize 5-mC (Jin et al., 2010), has a
distinct genomic distribution to 5-mC (being predominantly
found in gene promoters and gene bodies and rarely in intergenic
regions [Jin et al., 2011; Stroud et al., 2011]), is more abundant in
constitutive exons than alternatively spliced ones (Khare et al.,
2012) and has a lower afﬁnity to methyl-binding proteins than
5-mC (Hashimoto et al., 2012). 5-hmC appears to be present in all
tissues, although at differing levels, with the highest levels
observed in brain (Li and Liu, 2011) with enrichment in genes
involved in synapse-related functions (Khare et al., 2012); in
contrast the distribution of 5-mC appears to be relatively uniform
across tissues (Globisch et al., 2010). It has been suggested that
although some hydroxymethylated-CpG loci are stable during
aging, others are more dynamically altered (Szulwach et al.,
2011).
In 2011, two additional cytosine modiﬁcations were described in
mouse embryonic stem cells and somatic tissues (Inoue et al., 2011;
Ito et al., 2011). 5-formylcytosine (5-fC) and 5-carboxylcytosine
(5-caC) were found to result from the further oxidation of 5-hmC
by ten eleven translocation proteins (Ito et al., 2011), suggesting
that these modiﬁcations represent further steps along thedemethylation pathway (Inoue et al., 2011). Although little is
known about their functional role and prevalence in the healthy
genome, recent studies have mapped 5-fC to gene regulatory ele-
ments, namely poised enhancers and CpG island promoters (Raiber
et al., 2012; Song et al., 2013).
The aim of the present study was to investigate the relative
abundance of the four described cytosine modiﬁcations across two
distinct anatomic brain regions (entorhinal cortex [EC] and cere-
bellum [CER]) in tissue obtained from AD cases and elderly
controls.2. Methods
2.1. Subjects and sample preparation
Formalin-ﬁxed tissue punches from the EC and CER were
obtained from AD cases (n ¼ 13) and cognitively normal elderly
control (CTL) subjects (n ¼ 8) from the MRC London Neurodegen-
erative Diseases Brain Bank (http://www.kcl.ac.uk/iop/depts/cn/
research/MRC-London-Neurodegenerative-Diseases-Brain-Bank/
MRC-London-Neurodegenerative-Diseases-Brain-Bank.aspx). Sam-
ple demographics are shown in Supplementary Table 1.
Fig. 2. Differences in nuclear ﬂuorescence intensity for each cytosine modiﬁcation in tissue from control (black) and AD (white) brains. Data are represented as the mean ﬂuo-
rescence per positive cell across all samples in the group (SEM). (A) There was no difference in 5-mC levels in AD samples, or across brain regions. (B) There was an overall effect of
disease on 5-hmC levels (p < 0.001), with a decrease in 5-hmC in AD samples compared with control in both the EC (p < 0.001) and CER (p ¼ 0.0476) (C) There was a signiﬁcant
effect of brain region on 5-fC levels (p < 0.001), with a signiﬁcant difference in 5-fC in EC compared with CER in AD (p ¼ 0.0026) (C). There was no difference in 5-caC in AD samples,
or across brain regions (D). Between groups p-values are tabulated (E). Abbreviations: AD, Alzheimer’s disease; 5-caC, 5-carboxylcytosine; CER, cerebellum; EC, entorhinal cortex;
5-fC, 5-formylcytosine; 5-hmC, 5-hydroxymethylcytosine; 5-mC, 5-methylcytosine; SEM, standard error of the mean.
D. Condliffe et al. / Neurobiology of Aging xxx (2014) 1e5 32.2. Immunoﬂuorescence
Samples were cryosectioned at 10 mm on a freezing Cryostat
before immunostaining with antibodies purchased from Active
Motif (CA, US) against 5-mC (Cat# 39649), 5-hmC (Cat# 39791),
5-caC (Cat# 61225), and 5-fC (Cat# 61223). Brieﬂy following an-
tigen retrieval (10 mM sodium citrate, 0.05% tween, pH 6.0, 80 C),
quenching of endogenous immunoﬂuorescence (300 mM glycine),
and membrane permeabilization (Triton-X), nonspeciﬁc binding
was blocked with 10% normal goat serum (Vector Laboratories) for
30 minutes before the addition of primary antibody (1:2000
dilution in 5% normal goat serum for 16 hours at 4 C). Slides were
incubated with biotinylated goat secondary antibody (Vector
Laboratories, Peterborough, UK) at 1:200 dilution for 1 hour, fol-
lowed by streptavidin-AF596 (Life Technologies, CA, USA) for
1 hour. To minimize auto-ﬂuorescence, samples were incubatedwith 0.3% Sudan Black for 30 minutes then mounted on coverslips
with Prolong-Gold with 40,6-diamidino-2-phenylindole (DAPI)
(Life Technologies, California, US).
2.3. Microscopy and analysis
Appropriate controls to demonstrate the speciﬁcity of anti-
bodies were included for every sample, including a primary
antibody control (incubation with the relevant nucleoside [Inoue
et al., 2011] before staining) and a secondary antibody control
(incubation in the absence of primary antibody). Immunoﬂuo-
rescence images were acquired on a Zeiss Axio Imager II at 40
magniﬁcation, with all camera and microscope settings constant
for all images taken within each antibody. The two control sec-
tions were checked by eye for each slide followed by the capture
of 10 images from nonoverlapping ﬁelds of view taken from each
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ImageJ script to determine the level of ﬂuorescence per positive
cell that applied a threshold pixel value to the red (AF546)
channel to create a binary mask image, which was then used as a
template for measuring the red ﬂuorescence. A binary mask was
used as it allowed the measurement of ﬂuorescence only within
the nuclei and removed any nonspeciﬁc background staining
from the analysis. We then calculated the intensity within each
nuclei staining positive in a given image and generated an
average per cell by dividing the total ﬂuorescence intensity in the
binary mask of a given image by the number of nuclei staining
positive in that image. This was then averaged across the 10
images. Data were assessed for normality and analyzed ﬁrst using
mixed effects modeling in STATA (StataCorp) to identify differ-
ences between AD cases and controls across each brain region,
while controlling for age and gender. When an association with
disease was observed we used linear modeling to look for dif-
ferences associated with Braak score, a measure of disease stage
(Braak and Braak, 1991) while controlling for age and gender.
3. Results and discussion
3.1. Each cytosine modiﬁcation is present in adult human brain
Initially, we sought to investigate whether each of the four-
cytosine modiﬁcations could be detected in adult human brain.
Because two of the antibodies (5-fC and 5-caC) had yet to be tested
in human samples, we ﬁrst stained sections of human EC with
antibodies speciﬁc to each modiﬁcation (Fig. 1). Staining of all four
antibodies co-localized with DAPI conﬁrming nuclear staining. To
test for nonspeciﬁc staining, each antibody was incubated with its
complimentary nucleoside before staining to act as a negative
control. As expected no staining was observed, demonstrating the
speciﬁcity of the antibodies. Similarly, no staining was observed in
the absence of the primary antibody. Once we had established the
speciﬁcity of the antibodies and the presence of each cytosine
modiﬁcation in human brain we compared their relative abun-
dance in two distinct anatomic brain regions and whether
different levels are present in AD cases compared with controls
(Fig. 2).
3.2. Cross-tissue differences in 5-mC in AD
Recent studies have demonstrated differential DNA methylation
at speciﬁc loci between EC and CER (Davies et al., 2012) and be-
tween AD and controls (Bakulski et al., 2012). Here, we found no
signiﬁcant difference in global 5-mC level between brain regions
(p ¼ 0.286) nor in disease (p ¼ 0.401) (Fig. 2A). Similarly, two
previous studies have also demonstrated no difference in 5-mC in
CER in AD (Mastroeni et al., 2009, 2010), however, one of these
studies showed decreased 5-mC in AD EC (Mastroeni et al., 2010).
Discrepancies between that study and our own could be because of
a number of technical issues, including different reagents, fewer
samples within our study, different sample cohorts and peri-
mortem differences such as postmortem delay and brain pH, where
their inﬂuence on DNAmethylation are currently unknown (Pidsley
and Mill, 2011).
3.3. Cross-tissue differences in 5-hmC in AD
We found an overall signiﬁcant effect of disease status (p <
0.001) but not brain region (p ¼ 0.061) on 5-hmC levels, with a
signiﬁcant decrease in 5-hmC in AD comparedwith control in both
EC (p < 0.001) and CER (p ¼ 0.0476) (Fig. 2B). We also observed a
signiﬁcant negative correlation between global 5-hmC and Braakscore, a measure of AD neuropathology and disease stage, in both
the EC (r ¼ 0.6927, p < 0.001) and CER (r ¼ 0.2795, p ¼ 0.029). Our
ﬁndings indicate that there is a global reduction in 5-hmC in AD
brain that is present in both regions of primary neuropathology
(EC) and regions largely devoid of neuropathology (CER), sug-
gesting a potential global response to the disease process. Our
results also concur with a recent study by Chouliaras et al., 2013
that identiﬁed AD- and neuropathology-associated reductions in
glial 5-hmC in the hippocampus and in the affected sib of a
monozygotic twin pair discordant for AD.
3.4. Cross-tissue differences in 5-fC and 5-caC in AD
We found an overall signiﬁcant effect of brain area (p < 0.001),
but not of disease (p ¼ 0.372) on 5-fC abundance, with signiﬁcantly
less 5-fC in EC than CER in AD (p ¼ 0.0026), and a near-signiﬁcant
reduction in controls (p ¼ 0.072) (Fig. 2C). There was no signiﬁ-
cant effect of brain area (p¼ 0.810), nor disease (p¼ 0.194) on 5-caC
levels (Fig. 2D). Both 5-fC and 5-caC are reported to be present at 10
to 1000-fold lower levels than 5-hmC in primordial germ cells
(Vincent et al., 2013), accounting for between 3 and 20 parts per
million cytosines across the genome (Song et al., 2012).
4. Conclusions
This study conﬁrmed that all four cytosine modiﬁcations are
present in adult human brain and that there is a signiﬁcant
reduction in 5-hmC in AD, across two different anatomic regions of
the brain. These data concur with previous reports of an AD-
associated reduction in 5-hmC in the hippocampus (Chouliaras
et al., 2013). Although there was a regional difference in 5-fC
levels, no AD-associated changes in 5-mC, 5-fC, or 5-caC were
observed, although previous reports have shown decrements in
5-mC in AD EC and hippocampus (Chouliaras et al., 2013;
Mastroeni et al., 2010). Given the relatively small numbers of
samples assessed in this study, further research investigating the
speciﬁcity of the differences in 5-hmC and 5-fC, we report,
particularly across different neuron and glia subtypes, will be of
particular interest to the ﬁeld. Our observation has implications for
current efforts to map site-speciﬁc changes in 5-mC in AD using
bisulﬁte-based approaches that cannot distinguish between 5-mC
and 5-hmC and suggests that disease-associated differentially
methylated regions should be interrogated using approaches that
can speciﬁcally target these modiﬁcations (e.g., oxidative-bisulﬁte
sequencing [Booth et al., 2012, 2013]).
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